As Neurocrine Biosciences INC (NBIX) Stock Value Rose, Fosun International LTD Has Lifted Holding

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) LogoInvestors sentiment increased to 1.44 in 2019 Q1. Its up 0.45, from 0.99 in 2018Q4. It is positive, as 37 investors sold NBIX shares while 71 reduced holdings. 45 funds opened positions while 110 raised stakes. 101.77 million shares or 17.27% more from 86.79 million shares in 2018Q4 were reported. Trexquant Inv Lp reported 0.13% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). 8,900 were accumulated by Virginia Retirement Systems Et Al. Cubist Systematic Strategies Limited Liability Company holds 0.04% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) or 15,680 shares. Glenmede Trust Co Na has 0% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). First Mercantile invested in 561 shares or 0.01% of the stock. Rafferty Asset Mngmt Llc reported 0.09% stake. The Alabama-based Weiss Multi has invested 0.14% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Eaton Vance Mngmt invested 0.03% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). The Nevada-based Navellier & Associate has invested 0.28% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Cornerstone Advsrs holds 0% or 25 shares in its portfolio. Sei Invs Com stated it has 53,021 shares. Bnp Paribas Arbitrage has invested 0% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Zeke Advsr Lc holds 8,495 shares or 0.07% of its portfolio. New York-based Morgan Stanley has invested 0% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Federated Investors Pa holds 9,830 shares or 0% of its portfolio.

Fosun International Ltd increased its stake in Neurocrine Biosciences Inc (NBIX) by 62.58% based on its latest 2019Q1 regulatory filing with the SEC. Fosun International Ltd bought 39,000 shares as the company’s stock rose 29.28% . The institutional investor held 101,323 shares of the health care company at the end of 2019Q1, valued at $8.67M, up from 62,323 at the end of the previous reported quarter. Fosun International Ltd who had been investing in Neurocrine Biosciences Inc for a number of months, seems to be bullish on the $8.69B market cap company. The stock increased 0.53% or $0.5 during the last trading session, reaching $94.88. About 483,284 shares traded. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has declined 2.64% since August 15, 2018 and is downtrending. It has underperformed by 2.64% the S&P500.

Fosun International Ltd, which manages about $1.57 billion US Long portfolio, decreased its stake in Cowen Inc by 429,940 shares to 92,221 shares, valued at $1.34 million in 2019Q1, according to the filing. It also reduced its holding in Colony Cap Inc New by 7.04 million shares in the quarter, leaving it with 9.64M shares, and cut its stake in Yy Inc (NASDAQ:YY).

More notable recent Neurocrine Biosciences, Inc. (NASDAQ:NBIX) news were published by: which released: “Baird sees 37% upside in Regeneron in premarket analyst action – Seeking Alpha” on August 07, 2019, also with their article: “First Week of April 18th Options Trading For Neurocrine Biosciences (NBIX) – Nasdaq” published on March 07, 2019, published: “Achillion (ACHN) Reports Wider Y/Y Loss in Q2, Revenues Nil – Nasdaq” on August 09, 2019. More interesting news about Neurocrine Biosciences, Inc. (NASDAQ:NBIX) were released by: and their article: “OSTK, NBIX among premarket gainers – Seeking Alpha” published on July 30, 2019 as well as‘s news article titled: “Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Top Estimates – Nasdaq” with publication date: July 29, 2019.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Ratings Coverage

Among 8 analysts covering Neurocrine (NASDAQ:NBIX), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Neurocrine has $127 highest and $87 lowest target. $108.25’s average target is 14.09% above currents $94.88 stock price. Neurocrine had 15 analyst reports since March 12, 2019 according to SRatingsIntel. Piper Jaffray maintained the stock with “Overweight” rating in Tuesday, July 30 report. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) earned “Buy” rating by H.C. Wainwright on Wednesday, March 13. Credit Suisse maintained the shares of NBIX in report on Tuesday, July 30 with “Outperform” rating. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has “Buy” rating given on Tuesday, March 12 by Cantor Fitzgerald. As per Monday, April 22, the company rating was upgraded by JP Morgan. The company was maintained on Wednesday, March 13 by Cowen & Co. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has “Hold” rating given on Tuesday, March 12 by Leerink Swann.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.